You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. HF Radar Calibration with Automatic Identification System Ships of Opportunity

    SBC: CODAR OCEAN SENSORS, LTD            Topic: 841

    Over 300 HF RADARs worldwide are producing ocean surface data that is used in oil spill response, search & rescue, vessel traffic management, and research. In the U.S. there are 100+ systems supplying real-time data to the Coast Guard, NOAA IOOS, OR&R and other operational groups. To provide the highest quality data to stakeholders, systems should be calibrated by measuring the receive antenna p ...

    SBIR Phase II 2011 Department of CommerceNational Oceanic and Atmospheric Administration
  2. Cost Competitive Wave Energy Without Moving Parts

    SBC: Oscilla Power, Inc.            Topic: 815

    Oscilla Power, Inc. (OPI) is developing a utility-scale wave energy harvester that is enabled by low cost and readily-available magnetostrictive alloys. T his device, which utilizes no moving parts, has the potential to deliver predictable quantities of electric power to coastal utilities, industrial users, and remote facilities at costs competitive with coal or gas. The Phase I project demonstra ...

    SBIR Phase II 2011 Department of CommerceNational Oceanic and Atmospheric Administration
  3. Identifying Drugs to Treat Age-Dependent Neurodegeneration

    SBC: EXPRESSION DRUG DESIGN LLC            Topic: NIA

    DESCRIPTION (provided by applicant): Defining the molecular mechanism that leads to cellular aging and neural degeneration has proven to be difficult. Many types of damage are thought to contribute to senescence and neural degeneration and include mitochondrial and nuclear DNA mutations, protein misfolding, aggregate formation, reactive oxygen species (ROS), and stem cell senescence. However, a co ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  4. A Monoclonal Antibody Immunoprotectant for Ebola Virus

    SBC: MAPP BIOPHARMACEUTICAL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The National Institutes of Health considers the development of therapeutics against potential bioterrorism agents a national research priority. There is a particular need for immunotherapeutics against Ebola virus (a Category A agent). Because of Ebola's lethality and reports that it has been weaponized, public health officials and defense agencies have mo ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Chemical Stabilization of shRNAs and their development as hepatitis C drugs

    SBC: Somagenics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is a worldwide health problem, and its treatment and prevention remain a major challenge. Existing therapies are only partially effective and have serious side effects. No vaccine is currently available. RNA interference (RNAi) offers a novel therapeutic approach for treating HCV infections. We have identified a class of shRNAs, called s ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  6. A Cell-based Assay for Botulinum Neurotoxin Detection and Development

    SBC: BIOSENTINEL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most toxic substances known to humans, causing respiratory failure. Because of their lethality and ease of production, the Department of Defense (DoD) designates BoNTs as a categoryA bioterrorism agent. Developing effective, post-exposure antagonists to BoNT is among DoD's top priorities. Despite their lethality, BoNT ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical development of a tenofovir intravaginal ring for HIV prophylaxis

    SBC: AURITEC PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Large efforts are currently underway funded by the NIH, the Gates foundation, and the WHO, to reduce the spread of HIV transmission by developing an effective microbicide. The CAPRISA trial with tenofovir gel is the first demonstration of prophylaxis against HIV and HSV using a topical microbicide. Because protection increased with increasing adherence, and bec ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs

    SBC: TRANSDERM, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): RNA interference (RNAi) has the potential to revolutionize treatment of dominant genetic disorders. Small inhibitory RNAs (siRNAs) are highly potent and selective, demonstrating remarkable single-nucleotide specificity.Clinical trials using siRNAs are currently underway for a number of indications including skin. Facilitated by Phase 1 funding, a small one pati ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Exploiting synthetic lethality of hematopoietic lineage cells to develop novel ta

    SBC: Cellecta, Incorporated            Topic: NCI

    DESCRIPTION (provided by applicant): Targeted therapies have the ability to specifically interact with and block proliferation of cancer cells by interfering with targeted gene products required for the malignant phenotype. Unlike conventional cancer chemotherapies, targeted therapies do not harm normal cells of the body. This class of therapeutic has been met with considerable clinical success i ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Monoclonal Antibody to FGF2 for Treatment of Hepatocellular Carcinoma and Other C

    SBC: GALAXY BIOTECH, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The objective of the proposed research is to thoroughly characterize a humanized monoclonal antibody (mAb) that binds and inhibits human Fibroblast Growth Factor 2 (FGF2; basic FGF) for potential use in cancer therapy.FGF2 can directly stimulate tumor cell proliferation and also induces migration, proliferation and differentiation of endothelial cells, so is a ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government